328 related articles for article (PubMed ID: 22705022)
21. Novel chimeric histone deacetylase inhibitors: a series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity.
Mahboobi S; Sellmer A; Winkler M; Eichhorn E; Pongratz H; Ciossek T; Baer T; Maier T; Beckers T
J Med Chem; 2010 Dec; 53(24):8546-55. PubMed ID: 21080629
[TBL] [Abstract][Full Text] [Related]
22. Synthesis, evaluation and molecular modeling of cyclic tetrapeptide histone deacetylase inhibitors as anticancer agents.
Huang D; Li X; Sun L; Xiu Z; Nishino N
J Pept Sci; 2012 Apr; 18(4):242-51. PubMed ID: 22253009
[TBL] [Abstract][Full Text] [Related]
23. 2-aroylindoles and 2-aroylbenzofurans with N-hydroxyacrylamide substructures as a novel series of rationally designed histone deacetylase inhibitors.
Mahboobi S; Sellmer A; Höcher H; Garhammer C; Pongratz H; Maier T; Ciossek T; Beckers T
J Med Chem; 2007 Sep; 50(18):4405-18. PubMed ID: 17691763
[TBL] [Abstract][Full Text] [Related]
24. 3-(4-Aroyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-propenamides as a new class of synthetic histone deacetylase inhibitors. 2. Effect of pyrrole-C2 and/or -C4 substitutions on biological activity.
Mai A; Massa S; Cerbara I; Valente S; Ragno R; Bottoni P; Scatena R; Loidl P; Brosch G
J Med Chem; 2004 Feb; 47(5):1098-109. PubMed ID: 14971890
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and biological evaluation of N-aryl salicylamides with a hydroxamic acid moiety at 5-position as novel HDAC-EGFR dual inhibitors.
Zuo M; Zheng YW; Lu SM; Li Y; Zhang SQ
Bioorg Med Chem; 2012 Jul; 20(14):4405-12. PubMed ID: 22698782
[TBL] [Abstract][Full Text] [Related]
26. Identification of a series of substituted 2-piperazinyl-5-pyrimidylhydroxamic acids as potent histone deacetylase inhibitors.
Angibaud P; Van Emelen K; Decrane L; van Brandt S; Ten Holte P; Pilatte I; Roux B; Poncelet V; Speybrouck D; Queguiner L; Gaurrand S; Mariën A; Floren W; Janssen L; Verdonck M; van Dun J; van Gompel J; Gilissen R; Mackie C; Du Jardin M; Peeters J; Noppe M; Van Hijfte L; Freyne E; Page M; Janicot M; Arts J
Bioorg Med Chem Lett; 2010 Jan; 20(1):294-8. PubMed ID: 19906529
[TBL] [Abstract][Full Text] [Related]
27. Structure and property based design, synthesis and biological evaluation of γ-lactam based HDAC inhibitors.
Choi E; Lee C; Park JE; Seo JJ; Cho M; Kang JS; Kim HM; Park SK; Lee K; Han G
Bioorg Med Chem Lett; 2011 Feb; 21(4):1218-21. PubMed ID: 21256006
[TBL] [Abstract][Full Text] [Related]
28. Discovery of adamantane based highly potent HDAC inhibitors.
Gopalan B; Ponpandian T; Kachhadia V; Bharathimohan K; Vignesh R; Sivasudar V; Narayanan S; Mandar B; Praveen R; Saranya N; Rajagopal S; Rajagopal S
Bioorg Med Chem Lett; 2013 May; 23(9):2532-7. PubMed ID: 23538115
[TBL] [Abstract][Full Text] [Related]
29. Synthesis and Biological Evaluation of 1-(2-Aminophenyl)-3-arylurea Derivatives as Potential EphA2 and HDAC Dual Inhibitors.
Zhu Y; Ran T; Chen X; Niu J; Zhao S; Lu T; Tang W
Chem Pharm Bull (Tokyo); 2016; 64(8):1136-41. PubMed ID: 27477652
[TBL] [Abstract][Full Text] [Related]
30. Synthesis and biological characterization of amidopropenyl hydroxamates as HDAC inhibitors.
Thaler F; Varasi M; Colombo A; Boggio R; Munari D; Regalia N; Rozio MG; Reali V; Resconi AE; Mai A; Gagliardi S; Dondio G; Minucci S; Mercurio C
ChemMedChem; 2010 Aug; 5(8):1359-72. PubMed ID: 20572281
[TBL] [Abstract][Full Text] [Related]
31. Design, synthesis and preliminary biological evaluation of N-hydroxy-4-(3-phenylpropanamido)benzamide (HPPB) derivatives as novel histone deacetylase inhibitors.
Jiao J; Fang H; Wang X; Guan P; Yuan Y; Xu W
Eur J Med Chem; 2009 Nov; 44(11):4470-6. PubMed ID: 19608304
[TBL] [Abstract][Full Text] [Related]
32. Design, synthesis and biological evaluation of N-phenylsulfonylnicotinamide derivatives as novel antitumor inhibitors.
Zhang H; Lu X; Zhang LR; Liu JJ; Yang XH; Wang XM; Zhu HL
Bioorg Med Chem; 2012 Feb; 20(4):1411-6. PubMed ID: 22277588
[TBL] [Abstract][Full Text] [Related]
33. Improved antiproliferative activity of 1,3,4-thiadiazole-containing histone deacetylase (HDAC) inhibitors by introduction of the heteroaromatic surface recognition motif.
Guan P; Wang L; Hou X; Wan Y; Xu W; Tang W; Fang H
Bioorg Med Chem; 2014 Nov; 22(21):5766-75. PubMed ID: 25311567
[TBL] [Abstract][Full Text] [Related]
34. Synthesis and molecular docking study of novel coumarin derivatives containing 4,5-dihydropyrazole moiety as potential antitumor agents.
Liu XH; Liu HF; Chen J; Yang Y; Song BA; Bai LS; Liu JX; Zhu HL; Qi XB
Bioorg Med Chem Lett; 2010 Oct; 20(19):5705-8. PubMed ID: 20800480
[TBL] [Abstract][Full Text] [Related]
35. Discovery of a series of small molecules as potent histone deacetylase inhibitors.
Zhang L; Wang X; Li X; Xu W
J Enzyme Inhib Med Chem; 2014 Jun; 29(3):333-7. PubMed ID: 23534931
[TBL] [Abstract][Full Text] [Related]
36. Design, synthesis and anticancer evaluation of acridine hydroxamic acid derivatives as dual Topo and HDAC inhibitors.
Chen J; Li D; Li W; Yin J; Zhang Y; Yuan Z; Gao C; Liu F; Jiang Y
Bioorg Med Chem; 2018 Aug; 26(14):3958-3966. PubMed ID: 29954683
[TBL] [Abstract][Full Text] [Related]
37. Design and synthesis of N-phenylacetyl (sulfonyl) 4,5-dihydropyrazole derivatives as potential antitumor agents.
Liu XH; Ruan BF; Liu JX; Song BA; Jing LH; Li J; Yang Y; Zhu HL; Qi XB
Bioorg Med Chem Lett; 2011 May; 21(10):2916-20. PubMed ID: 21486698
[TBL] [Abstract][Full Text] [Related]
38. Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates.
Suzuki T; Nagano Y; Kouketsu A; Matsuura A; Maruyama S; Kurotaki M; Nakagawa H; Miyata N
J Med Chem; 2005 Feb; 48(4):1019-32. PubMed ID: 15715470
[TBL] [Abstract][Full Text] [Related]
39. Identification and optimisation of a series of substituted 5-(1H-pyrazol-3-yl)-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.
Price S; Bordogna W; Bull RJ; Clark DE; Crackett PH; Dyke HJ; Gill M; Harris NV; Gorski J; Lloyd J; Lockey PM; Mullett J; Roach AG; Roussel F; White AB
Bioorg Med Chem Lett; 2007 Jan; 17(2):370-5. PubMed ID: 17095213
[TBL] [Abstract][Full Text] [Related]
40. Synthesis, molecular modeling and biological evaluation of 2-(benzylthio)-5-aryloxadiazole derivatives as anti-tumor agents.
Liu K; Lu X; Zhang HJ; Sun J; Zhu HL
Eur J Med Chem; 2012 Jan; 47(1):473-8. PubMed ID: 22119130
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
